Healthcare -
Biotechnology - NASDAQ - US
$ 3.58
0.562 %
$ 178 M
Market Cap
4.59
P/E
1. INTRINSIC VALUE
Balance Sheet
Puma Biotechnology, Inc.
| Current Assets | 148 M |
| Cash & Short-Term Investments | 101 M |
| Receivables | 32 M |
| Other Current Assets | 14.7 M |
| Non-Current Assets | 65.7 M |
| Long-Term Investments | 0 |
| PP&E | 5.09 M |
| Other Non-Current Assets | 60.6 M |
| Current Liabilities | 96.1 M |
| Accounts Payable | 5.51 M |
| Short-Term Debt | 50.9 M |
| Other Current Liabilities | 39.7 M |
| Non-Current Liabilities | 25.1 M |
| Long-Term Debt | 23.2 M |
| Other Non-Current Liabilities | 1.88 M |
EFFICIENCY
Earnings Waterfall
Puma Biotechnology, Inc.
| Revenue | 230 M |
| Cost Of Revenue | 64.4 M |
| Gross Profit | 166 M |
| Operating Expenses | 135 M |
| Operating Income | 31 M |
| Other Expenses | 688 K |
| Net Income | 30.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Puma Biotechnology, Inc.
| Net Income | 30.3 M |
| Depreciation & Amortization | 11.5 M |
| Capital Expenditures | -56 K |
| Stock-Based Compensation | 8.24 M |
| Change in Working Capital | -3.54 M |
| Others | -17.4 M |
| Free Cash Flow | 38.9 M |
Wall Street Analysts Price Targets
Puma Biotechnology, Inc.
PBYI has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
PBYI does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Puma Biotechnology, Inc.
Sold
0-3 MONTHS
312 K USD 6
3-6 MONTHS
0 USD 0
6-9 MONTHS
196 K USD 4
9-12 MONTHS
201 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement restricted stock units awarded to new hires in June 2025, as required by Nasdaq Listing Rule 5635(c)(4).
businesswire.com
- 2 weeks ago
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
- 3 weeks ago
Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment
Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, especially in pancreatic cancer, but pivotal data won't arrive until 2026. Alisertib's phase 2 trials in breast and lung cancer are ongoing, but lack of recent data keeps its potential speculative for now.
seekingalpha.com
- 3 weeks ago
Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain
Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
zacks.com
- 3 weeks ago
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
- 1 month ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award.
businesswire.com
- 1 month ago
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
zacks.com
- 1 month ago
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
- 1 month ago
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock
Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
zacks.com
- 2 months ago
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
- 2 months ago
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss of 5 cents per share.
zacks.com
- 2 months ago
Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director Investor Relations Alan Auerbach - President & Chief Executive Officer Jeff Ludwig - Chief Commercial Officer Heather Blaber - VP of Marketing Roger Storms - VP of Sales Maximo Nougues - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Operator Good afternoon. My name is Sherry, and I will be your conference call operator today.
seekingalpha.com
- 2 months ago
8. Profile
Summary
Puma Biotechnology, Inc. PBYI
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 178 M
Dividend Yield
0.00%
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Contact
10880 Wilshire Boulevard, Los Angeles, CA, 90024
https://www.pumabiotechnology.com
IPO
Date
April 24, 2012
Employees
172
Officers
Mr. Mariann Ohanesian
Senior Director of Investor Relations
Mr. Douglas Hunt B.Sc., FRAPS
Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer
Mr. Alan H. Auerbach
Founder, Chairman, President, Chief Executive Officer & Secretary
Mr. Maximo F. Nougues
Chief Financial Officer & Principal Accounting Officer